# Merck & Co., Inc. (MRK) offers human health pharmaceuticals across various areas.

*business · news · 2026-05-04 · Barchart*

## Key points

- Merck's acquisition of Terns Pharmaceuticals was for $53 per share, totaling $6.7 billion.
- The Terns acquisition expands Merck's hematology portfolio specifically with the TERN-701 molecule.
- Analysts expect Merck's EPS to decline by 45.4% to $4.90 for the current year.
- Merck stock has outperformed both the S&P 500 and healthcare sector ETF XLV over the last year.
- MRK's highest analyst price target is $150, implying a possible 33.7% upside from current prices.

**Companies:** Merck & Co., Inc., Terns Pharmaceuticals, Inc.
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1678987/do-wall-street-analysts-like-merck-co-stock)

---

Canonical: https://newsio.io/n/54e8344f-4d84-4f61-a90a-b3fa97c3d07f/merck-co-inc-mrk-offers-human-health-pharmaceuticals-across-various-areas-the-co
Summarized by Newsio from Barchart. https://newsio.io/how-it-works